医药行业周报：默沙东以1.12亿美元首付款引进翰森口服GLP-1激动剂

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical industry, expecting overall returns to exceed the CSI 300 Index by more than 5% over the next six months [4]. Core Insights - As of December 19, 2024, the pharmaceutical sector experienced a slight decline of -0.25%, underperforming the CSI 300 Index by 0.34 percentage points, ranking 13th among 31 sub-industries in the Shenwan classification [2]. - Notable performances within sub-industries include medical devices (+0.15%) and blood products (-0.19%), while hospitals (-1.26%) and offline pharmacies (-0.85%) lagged behind [2]. - A significant partnership was announced between Merck and Hansoh Pharmaceutical, involving a global exclusive licensing agreement for Hansoh's oral GLP-1 receptor agonist HS-10535, with an upfront payment of $112 million and potential milestone payments up to $1.9 billion [2][6]. Summary by Sections Market Performance - The pharmaceutical sector's performance on December 19, 2024, was -0.25%, with individual stocks showing varied results, such as a top gain of +9.29% for Qianying Biological and a top loss of -10.07% for Puli Pharmaceutical [2]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine: No rating - Biopharmaceuticals II: Neutral - Other pharmaceuticals: Neutral [2]. Company News - Guobang Pharmaceutical (605507) received a favorable FDA inspection report for its facility, indicating compliance with cGMP standards [2]. - Betta Pharmaceuticals (300558) announced FDA approval for its product, Ensacove, for treating ALK-positive non-small cell lung cancer [2]. - WuXi AppTec (603259) plans to invest in European biopharmaceutical projects through its subsidiaries [2].